Benjamin W Fischer-Valuck
Overview
Explore the profile of Benjamin W Fischer-Valuck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
711
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andruska N, Waters M, Fischer-Valuck B, Smith Z, Kim E, Reimers M, et al.
Clin Genitourin Cancer
. 2023 Sep;
21(6):653-659.e1.
PMID: 37704483
Background: Non-muscle invasive bladder cancer (non-MIBC) that is high-grade and confined to the lamina propria (HGT1) often has an aggressive clinical course. Currently, there is limited data on the comparative...
2.
Hogan J, Karraker P, Fischer-Valuck B, Vapiwala N, Mehta M, Perez C, et al.
Pract Radiat Oncol
. 2023 May;
13(5):e389-e394.
PMID: 37172757
Radiation oncology (RO) has seen declines in Medicare reimbursement (MCR) in the past decade under the current fee-for-service model. Although studies have explored decline in reimbursement at a per-code level,...
3.
Waters M, Andruska N, Fischer-Valuck B, Agabalogun T, Brenneman R, Gay H, et al.
Cureus
. 2023 Mar;
15(1):e34351.
PMID: 36874706
Introduction Stereotactic body radiation therapy (SBRT) for prostate adenocarcinoma (PCa) has demonstrated excellent biochemical recurrence-free survival, with studies showing improved BRFS with higher-dose SBRT. However, current studies have been underpowered...
4.
Patel S, Baumann B, Michalski J, Brenneman R, Zheng B, Gay H, et al.
Brachytherapy
. 2023 Jan;
22(3):310-316.
PMID: 36635202
Purpose: The addition of a brachytherapy (BT) boost to external beam radiotherapy (EBRT) reduces recurrence risk in men with high-risk prostate cancer (PCa) and may reduce PCa-mortality for Gleason grade...
5.
Henke L, Fischer-Valuck B, Rudra S, Wan L, Samson P, Srivastava A, et al.
Radiother Oncol
. 2022 Dec;
178:109428.
PMID: 36455686
Introduction: A kV imager coupled to a novel, ring-gantry radiotherapy system offers improved on-board kV-cone-beam computed tomography (CBCT) acquisition time (17-40 seconds) and image quality, which may improve CT radiotherapy...
6.
Andruska N, Agabalogun T, Fischer-Valuck B, Brenneman R, Huang Y, Gay H, et al.
Brachytherapy
. 2022 May;
21(5):617-625.
PMID: 35641370
Background: Current recommendations regarding radiotherapy treatment for unfavorable intermediate-risk prostate cancer (UIR-PCa) include external beam radiotherapy (EBRT) ± brachytherapy boost (BT) ± androgen deprivation therapy (ADT). The ideal radiotherapy treatment...
7.
Hogan J, Roy A, Karraker P, Pollock J, Griffin Z, Vapiwala N, et al.
Int J Radiat Oncol Biol Phys
. 2022 May;
114(1):47-56.
PMID: 35613687
Purpose: Radiation oncology (RO) has seen declines in Medicare reimbursement (MCR). However, there are no recent studies analyzing the contributions of specific billing codes to overall RO reimbursement. We compared...
8.
Andruska N, Fischer-Valuck B, Waters M, Juarez Diaz E, Agabalogun T, Kim E, et al.
J Urol
. 2022 Mar;
207(6):1235.
PMID: 35282697
No abstract available.
9.
Fischer-Valuck B, Patel S, Brenneman R, Christodouleas J, Sargos P, Kim E, et al.
Eur Urol Oncol
. 2022 Mar;
5(2):246-250.
PMID: 35249864
There are limited data on the role of local therapy for metastatic urothelial carcinoma of the bladder (mUC). In this retrospective cohort analysis, we queried the National Cancer Data Base...
10.
Fischer-Valuck B, Baumann B, Brown S, Filson C, Weiss A, Mueller R, et al.
Eur Urol Open Sci
. 2022 Mar;
37:80-89.
PMID: 35243392
Background: Elderly patients diagnosed with high-risk prostate cancer (PCa) present a therapeutic dilemma of balancing treatment of a potentially lethal malignancy with overtreatment of a cancer that may not threaten...